Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial

Research output: Contribution to journalArticle

Abstract

In a phase II study we assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine, cyclophosphamide capecitabine in patients with metastatic breast cancer, either as first-line (naïve group) or second-line or greater therapy (pre-treated group). Eligible patients had histologically or cytologically proven, hormone-receptor positive metastatic breast cancer. The primary end point was median time to progression (TTP). A total of 43 patients in the naïve group and 65 in the pre-treated group were enrolled. The median TTP was 25.1 months in the naïve group and 11.2 months in the pre-treated group. The most frequently reported grade 2 treatment-related adverse events were leukopenia and hand and foot syndrome. Metronomic combination of cyclophosphamide, capecitabine and vinorelbine showed significant activity and good tolerability in patients hormonal receptor positive, metastatic breast cancer patients.

Original languageEnglish
Pages (from-to)276-281
Number of pages6
JournalCancer Letters
Volume400
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Cyclophosphamide
Breast Neoplasms
Safety
Hand-Foot Syndrome
Leukopenia
Capecitabine
vinorelbine
Hormones
Drug Therapy
Therapeutics

Keywords

  • Breast cancer
  • Metronomic
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{de9c1f17a9ff4538b9bad842fba2db01,
title = "Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial",
abstract = "In a phase II study we assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine, cyclophosphamide capecitabine in patients with metastatic breast cancer, either as first-line (na{\"i}ve group) or second-line or greater therapy (pre-treated group). Eligible patients had histologically or cytologically proven, hormone-receptor positive metastatic breast cancer. The primary end point was median time to progression (TTP). A total of 43 patients in the na{\"i}ve group and 65 in the pre-treated group were enrolled. The median TTP was 25.1 months in the na{\"i}ve group and 11.2 months in the pre-treated group. The most frequently reported grade 2 treatment-related adverse events were leukopenia and hand and foot syndrome. Metronomic combination of cyclophosphamide, capecitabine and vinorelbine showed significant activity and good tolerability in patients hormonal receptor positive, metastatic breast cancer patients.",
keywords = "Breast cancer, Metronomic, Vinorelbine",
author = "Emilia Montagna and Antonella Palazzo and Patrick Maisonneuve and Giuseppe Cancello and Monica Iorfida and Angela Sciandivasci and Angela Esposito and Anna Cardillo and Manuelita Mazza and Elisabetta Munzone and Antonella Lai and Aron Goldhirsch and Marco Colleoni",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.canlet.2017.01.027",
language = "English",
volume = "400",
pages = "276--281",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer

T2 - A phase II trial

AU - Montagna, Emilia

AU - Palazzo, Antonella

AU - Maisonneuve, Patrick

AU - Cancello, Giuseppe

AU - Iorfida, Monica

AU - Sciandivasci, Angela

AU - Esposito, Angela

AU - Cardillo, Anna

AU - Mazza, Manuelita

AU - Munzone, Elisabetta

AU - Lai, Antonella

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2017/8/1

Y1 - 2017/8/1

N2 - In a phase II study we assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine, cyclophosphamide capecitabine in patients with metastatic breast cancer, either as first-line (naïve group) or second-line or greater therapy (pre-treated group). Eligible patients had histologically or cytologically proven, hormone-receptor positive metastatic breast cancer. The primary end point was median time to progression (TTP). A total of 43 patients in the naïve group and 65 in the pre-treated group were enrolled. The median TTP was 25.1 months in the naïve group and 11.2 months in the pre-treated group. The most frequently reported grade 2 treatment-related adverse events were leukopenia and hand and foot syndrome. Metronomic combination of cyclophosphamide, capecitabine and vinorelbine showed significant activity and good tolerability in patients hormonal receptor positive, metastatic breast cancer patients.

AB - In a phase II study we assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine, cyclophosphamide capecitabine in patients with metastatic breast cancer, either as first-line (naïve group) or second-line or greater therapy (pre-treated group). Eligible patients had histologically or cytologically proven, hormone-receptor positive metastatic breast cancer. The primary end point was median time to progression (TTP). A total of 43 patients in the naïve group and 65 in the pre-treated group were enrolled. The median TTP was 25.1 months in the naïve group and 11.2 months in the pre-treated group. The most frequently reported grade 2 treatment-related adverse events were leukopenia and hand and foot syndrome. Metronomic combination of cyclophosphamide, capecitabine and vinorelbine showed significant activity and good tolerability in patients hormonal receptor positive, metastatic breast cancer patients.

KW - Breast cancer

KW - Metronomic

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=85012022762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012022762&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.01.027

DO - 10.1016/j.canlet.2017.01.027

M3 - Article

C2 - 28131905

AN - SCOPUS:85012022762

VL - 400

SP - 276

EP - 281

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -